Sign in
Taking people in South KoreaPhase 1/2

Testing MK-4208 in adults with chronic myeloid leukemia

Tests MK-4208 for safety and dose levels in adults with chronic myeloid leukemia.

Key facts

Who runs it
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Where
Anyang-si, Busan, Daegu, and Uijeongbu-si, South KoreaSee the 4 sitesAlso in 8 other countries, 49 sites
Registry title
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Status
Recruiting
Phase
Phase 1/2
People taking part
330 people, planned
Started
26 Mar 2024
Expected to end
31 May 2030
Type of study
Interventional, 10 groups
Treatments tested
  • MK-4208
Record updated
15 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic myeloid leukemia (CML) in the chronic phase. Their earlier TKI treatment must have failed, worked poorly, or caused side effects they could not tolerate.

Age
18 to 64 years
Sex
All sexes can join.
Disease stage
BCR-ABL1 positive chronic myeloid leukemia in the chronic phase, confirmed by cell tests.
Earlier treatment
Must have had at least 1 earlier tyrosine kinase inhibitor (TKI) with treatment failure, a weak response, or intolerance. Earlier asciminib is allowed. No cancer drug treatment in the 7 days before the first dose.
Biomarker or test result
BCR-ABL1 positive CML.

Main reasons for not taking part

  • Cancer drug treatment (including TKIs, interferon-alfa, antibodies, chemotherapy) or other experimental treatment within 7 days before the first dose
  • Side effects from earlier cancer treatment that have not gone down to Grade 2 or the starting level
  • Organ function that is not adequate on local lab tests
  • ECOG performance status score above 2

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • Have an established cytopathologically confirmed diagnosis of breakpoint cluster region::Abelson (BCR-ABL1) positive Chronic Myeloid Leukemia (CML) in Chronic Phase
  • Have received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance
  • Prior treatment with asciminib is allowed
  • Adequate organ function, as assessed by local laboratory

Who cannot take part

  • Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of MK-4208/TERN-701
  • Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in South Korea

Also in 8 other countries, 49 sites

  • Hallym University Sacred Heart HospitalAnyang-si, South KoreaContact: Toll Free NumberTaking people
  • Dong-A University HospitalBusan, South KoreaContact: Toll Free NumberTaking people
  • Keimyung University Dongsan HospitalDaegu, South KoreaContact: Toll Free NumberTaking people
  • Uijeorigbu Eulji Medical Center, Eulji UniversityUijeongbu-si, South KoreaContact: Toll Free NumberTaking people

About the trial

What the trial wants to find out

Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer.

Read full original descriptionShow less

The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.

The 10 groups in the trial

  • Part 1 - MK-4208 160 mg once daily (QD)Treatment being tested

    Participants receive MK-4208 160 mg orally QD.

    Treatment: MK-4208

  • Part 1- MK-4208 320 mg QDTreatment being tested

    Participants receive MK-4208 320 mg orally QD.

    Treatment: MK-4208

  • Part 1- MK-4208 400 mg QDTreatment being tested

    Participants receive MK-4208 400 mg orally QD.

    Treatment: MK-4208

  • Part 1- MK-4208 500 mg QDTreatment being tested

    Participants receive MK-4208 500 mg orally QD.

    Treatment: MK-4208

  • Part 2 - MK-4208 320 mg QDTreatment being tested

    Participants receive MK4208 320 mg orally QD.

    Treatment: MK-4208

  • Part 2 - MK-4208 500 mg QDTreatment being tested

    Participants receive MK4208 500 mg orally QD.

    Treatment: MK-4208

  • Part 2m - MK-4208 320 mg twice per day (BID)Treatment being tested

    Participants receive MK4208 320 mg orally BID.

    Treatment: MK-4208

  • Part 2m - MK-4208 500 mg QDTreatment being tested

    Participants receive MK-4208 500 mg orally QD.

    Treatment: MK-4208

  • Part 2m - MK4208 500 mg BIDTreatment being tested

    Participants receive MK4208 500 mg orally BID.

    Treatment: MK-4208

  • Part 3 - MK-4208 500 mg QDTreatment being tested

    Participants receive MK-4208 500 mg QD

    Treatment: MK-4208

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
Plain-language title
Testing MK-4208 in adults with chronic myeloid leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06163430, who can take part
Record updated
15 October 2026